LoginSignup
Evotec logo

Evotec

Stock
Stock
ISIN: DE0005664809
Ticker: EVT
DE0005664809
EVT

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Evotec is $616.14M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Evotec's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.287. EPS indicates the company's profitability on a per-share basis.
Currently, 10 analysts cover Evotec's stock, with a consensus target price of $5.548. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Evotec reported a revenue of $832.30M.
Evotec's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$41.76M. EBITDA measures the company's overall financial performance.
Evotec has a free cash flow of -$186.94M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Evotec employs approximately 4,553 people. It operates in the Health Care sector, specifically within the Miscellaneous Commercial Services industry.
The free float of Evotec is 148.08M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$616.14M
EPS (TTM) 
-$1.287
Free Float 
148.08M
Revenue (TTM) 
$832.30M
EBITDA (TTM) 
-$41.76M
Free Cashflow (TTM) 
-$186.94M

Pricing

1D span
$3.44$3.598
52W span
$3.444$8.506

Analyst Ratings

The price target is $5.548 and the stock is covered by 10 analysts.

Buy

3

Hold

7

Sell

0

Information

Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the Shared R&D and Just–Evotec Biologics segments. The Shared R&D segment includes drug discovery and development services and solutions. The Just–Evotec Biologics segment provides services related to designing, discovering, developing, and manufacturing of modern biotherapeutics. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, Charles Weissmann, and Nobel Laureate on December 8, 1993 and is headquartered in Hamburg, Germany.

Employees
4,553
Industries
Miscellaneous Commercial Services
Sector
Health Care

Identifier

ISIN
DE0005664809
Primary Ticker
EVT

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin